- Home
- CVR vs LPTX Comparison
CVR vs LPTX Comparison
Compare CVR & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- LPTX
- Stock Information
- Founded
- CVR 1920
- LPTX 2011
- Country
- CVR United States
- LPTX United States
- Employees
- CVR N/A
- LPTX N/A
- Industry
- CVR Industrial Machinery/Components
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVR Industrials
- LPTX Health Care
- Exchange
- CVR Nasdaq
- LPTX Nasdaq
- Market Cap
- CVR 9.8M
- LPTX 11.1M
- IPO Year
- CVR N/A
- LPTX N/A
- Fundamental
- Price
- CVR $10.10
- LPTX $0.31
- Analyst Decision
- CVR
- LPTX Hold
- Analyst Count
- CVR 0
- LPTX 1
- Target Price
- CVR N/A
- LPTX N/A
- AVG Volume (30 Days)
- CVR 2.5K
- LPTX 710.1K
- Earning Date
- CVR 11-11-2025
- LPTX 11-12-2025
- Dividend Yield
- CVR 1.23%
- LPTX N/A
- EPS Growth
- CVR N/A
- LPTX N/A
- EPS
- CVR N/A
- LPTX N/A
- Revenue
- CVR $25,617,681.00
- LPTX N/A
- Revenue This Year
- CVR N/A
- LPTX N/A
- Revenue Next Year
- CVR N/A
- LPTX N/A
- P/E Ratio
- CVR N/A
- LPTX N/A
- Revenue Growth
- CVR N/A
- LPTX N/A
- 52 Week Low
- CVR $8.15
- LPTX $0.22
- 52 Week High
- CVR $22.27
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- CVR 44.60
- LPTX 55.37
- Support Level
- CVR $9.01
- LPTX $0.28
- Resistance Level
- CVR $10.24
- LPTX $0.29
- Average True Range (ATR)
- CVR 0.34
- LPTX 0.02
- MACD
- CVR 0.10
- LPTX 0.00
- Stochastic Oscillator
- CVR 71.07
- LPTX 79.89
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.